- >
- News & Events
- >
- Press Releases
Press Releases
Page 1 of 31
ONXEO provides update on the Development Program for its first-in-class drug candidate AsiDNATM
Phase 1b/2 trial of AsiDNATM in combination with olaparib initiated in the United States in recurrent ovarian, breast and metastatic […]
01/25/2023
Onxeo advances its second lead candidate OX425 for the treatment of solid tumors
OX425 is a novel DDR Decoy Agonist which also mediates multiple immunostimulatory effects, making it a promising candidate for combination […]
11/30/2022
Onxeo Reports its Half-Year 2022 Financial Results and Provides an Update on its Activities
Refocusing R&D efforts as well as accelerating preclinical and clinical programs globally Cash position of €26.9 million as of June […]
09/13/2022
High-Grade Glioma Relapse in Children: Onxeo announces the enrollment of the first patient in the phase 1b/2 clinical study conducted by the European ITCC consortium and sponsored by Institut Curie
Paris (France), September 1st, 2022 – 8 pm CEST – Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North[1]: ONXEO), a […]
09/01/2022
Onxeo announces that Nasdaq approved the delisting of its shares from the First North Growth market in Copenhagen
Last day of trading on the First North Growth market on November 8, 2022 Listing on Euronext Growth Paris remains […]
08/30/2022
Combined General Meeting of August 17, 2022: Onxeo shareholders approve withdrawal from the Nasdaq First North market in Copenhagen
Company to submit delisting request to Nasdaq Paris (France), August 17, 2022 – 08:00 pm CEST – Onxeo S.A. […]
08/17/2022
Combined General Meeting of August 17, 2022: availability of preparatory documents and participation & voting procedures
Paris (France), July 29, 2022 – 06:30 pm CEST – Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North: ONXEO), a […]
07/29/2022
Onxeo announces a Combined General Meeting on August 17, 2022
Paris (France), July 12, 2022 – 07:00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: […]
07/12/2022
Initial IND application for AsiDNA Granted “Study May Proceed” by the U.S. FDA
Onxeo to initiate its first phase 1b/2 trial in the United States in patients with solid tumors Paris (France), […]
06/30/2022
Onxeo: Proceedings of the Combined Shareholders’ Meeting of June 15, 2022
All resolutions voted in accordance with Board of Directors’ recommendations Khalil Barrage, Managing Director of Invus’ public equity investments division, […]
06/16/2022
Page 1 of 31